CML president and CEO Brian Scanlan said CML supports both increasing demand for its commercial products as well as its healthy pipeline of API’s in later phases of clinical development.
”By making these new investments, we show our commitment to support our loyal client base at the most critical point, when quality and timely delivery are imperative," Scanlan added.
The expansion will include additional reactor capacity, isolation equipment and additional investments in engineering controls.
CML European Business Development director Roger McDonald said CML is the long-term partner for complex API development projects.
"Even clients in Phase I have the comfort of knowing they can potentially stay with us through product launch – plan for success!" McDonald added.
The expansion is the result of continued demand for larger scale API manufacturing services, according to CML.